Company intelligence / Profile preview

Dymium

Garching, Bavaria, Germanydymium.io ↗

Ownership: Private
Development stage: Other

Overview

Dymium has developed a novel minimally invasive method for the residue-free removal of kidney stones using magnetic separation. The approach involves transforming kidney stone fragments into magnetizable objects with a biocompatible agent and extracting them magnetically. This innovation aims to improve surgical outcomes and reduce recurrence rates. The company has won several startup awards but no published clinical trial results yet.

Therapeutic areas: Nephrology
Modalities: DeviceBiocompatible agent
Industry: Surgical Medical Devices

Partnerships

Collaboration with Technical University of Munich; no major pharma/biotech partnerships disclosed

Beyond the preview

Go deeper on Dymium.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dymium.

Explore the full profile